



Truvada® (emtricitabine/tenofovir disoproxil fumarate) – Expanded indication

- On May 15, 2018, the [FDA announced](#) the approval of [Gilead's Truvada \(emtricitabine \[FTC\]/tenofovir disoproxil fumarate \[TDF\]\)](#), in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually active human immunodeficiency virus type 1 (HIV-1) in at-risk adolescents weighing at least 35 kg.
 - Previously, Truvada was only approved for PrEP in adults at high risk.
 - Individuals must have a negative HIV-1 test immediately prior to initiating Truvada for HIV-1 PrEP.
- Truvada is also approved for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 17 kg.
- In the U.S., adolescents and young adults 13-24 years of age comprised 21% of all new HIV-1 infections in 2016, and 81% of the infections were among young men who have sex with men.
- The approval of Truvada's expanded indication is supported by data from well-controlled studies in adults, and additional data from safety and pharmacokinetic studies in previously conducted trials. The safety, adherence, and resistance were evaluated in a single-arm, open-label trial in 67 HIV-1 uninfected at-risk adolescent men who have sex with men. The safety of Truvada in this population was similar to that observed in the adult HIV-1 PrEP trials.
- Truvada carries a boxed warning regarding post-treatment acute exacerbation of hepatitis B and risk of drug resistance with use of Truvada for HIV-1 PrEP in undiagnosed early HIV-1 infection.
- In uninfected adults and adolescents weighing at least 35 kg, the recommended dosage of Truvada for HIV-1 PrEP is one tablet (containing 200 mg FTC and 300 mg TDF) orally once daily.
 - Refer to the Truvada drug label for additional dosage information, including for treatment of HIV-1 infection



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.